Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
180 Life Sciences Corp (ATNF)
180 Life Sciences Corp (ATNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,458
  • Shares Outstanding, K 7,476
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,730 K
  • 60-Month Beta 0.50
  • Price/Sales N/A
  • Price/Cash Flow 0.05
  • Price/Book N/A
Trade ATNF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.12
  • Most Recent Earnings $-0.15 on 11/09/23
  • Latest Earnings Date 03/29/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 109.90%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1812 +4.58%
on 02/23/24
0.2500 -24.20%
on 02/20/24
-0.0216 (-10.23%)
since 01/23/24
3-Month
0.1501 +26.25%
on 12/18/23
0.3754 -49.52%
on 11/29/23
-0.1501 (-44.20%)
since 11/22/23
52-Week
0.1501 +26.25%
on 12/18/23
2.9300 -93.53%
on 02/28/23
-2.5305 (-93.03%)
since 02/23/23

Most Recent Stories

More News
Calling All Quality Control: Get Rid of These 3 Biotech Stocks ASAP!

High-interest rates are expected to impact the growth of the biotech industry. Therefore, fundamentally weak biotech stocks Bionano Genomics (BNGO), VBI Vaccines (VBIV), and 180 Life Sciences (ATNF) might...

ATNF : 0.1895 (-2.87%)
BNGO : 1.1400 (-1.72%)
VBIV : 0.5701 (+0.90%)
Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors

Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone...

ATNF : 0.1895 (-2.87%)
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”)...

ATNF : 0.1895 (-2.87%)
Pre-Market Brief: Stocks Climb As Recession Fears Ease, China Reopens Borders

March S&P 500 futures (ESH23) are trending up +0.72% this morning after three major U.S. benchmark indices closed higher on Friday as market participants digested a deluge of economic data against rate...

ESH23 : 3,957.05s (-0.09%)
ATNF : 0.1895 (-2.87%)
AMC : 4.44 (+0.45%)
EC : 11.80 (-1.17%)
AMTI : 0.2630 (-14.30%)
PTRA : 0.0670 (-25.56%)
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program

PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 0.1895 (-2.87%)
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

PALO ALTO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 0.1895 (-2.87%)
180 Life Sciences Corp. Issues Letter to Stockholders

PALO ALTO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage...

ATNF : 0.1895 (-2.87%)
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 0.1895 (-2.87%)
180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease

PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 0.1895 (-2.87%)
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time...

ATNF : 0.1895 (-2.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

180 Life Sciences Corp. is a clinical-stage biotechnology company. It is focused on the development of novel drugs for unmet needs in inflammatory diseases, fibrosis and pain. 180 Life Sciences Corp., formerly known as KBL Merger Corp. IV, is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 0.2181
2nd Resistance Point 0.2090
1st Resistance Point 0.1993
Last Price 0.1895
1st Support Level 0.1805
2nd Support Level 0.1714
3rd Support Level 0.1617

See More

52-Week High 2.9300
Fibonacci 61.8% 1.8681
Fibonacci 50% 1.5401
Fibonacci 38.2% 1.2120
Last Price 0.1895
52-Week Low 0.1501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar